Skip to main content
. 2020 Sep 25;11:532199. doi: 10.3389/fphar.2020.532199

Figure 8.

Figure 8

A representative low-magnification light photomicrographs (A) and score (B) display pERK1/2 fluorescence of whole lung samples from PBS-challenged/vehicle, ovalbumin (OVA)-challenged/vehicle, OVA-challenged/Rv3619c/Freund’s Incomplete Adjuvant (IFA), OVA-challenged/dexamethasone (DEX) (3 mg), OVA-challenged/Rv3619c/IFA/dexamethasone (DEX) (0.5 mg), and OVA-challenged/dexamethasone (DEX) (0.5 mg). OVA-challenged/vehicle treated mice had marked increase in pERK1/2 signals compared with PBS-challenged mice. Immunization with Rv3619c/IFA alone resulted in a significant reduction in the pERK1/2 signals compared to OVA-challenged/vehicle treated mice and was comparable to the high dose dexamethasone (3 mg). Immunization of mice with Rv3619c/IFA in combination with dexamethasone (0.5 mg) did not result in any significant enhancement of the effects of Rv3619c/IFA alone. Data are expressed as mean ± SEM (n = 5). #P < 0.05 versus time-matched PBS-challenged mice. *P < 0.05 versus time-matched OVA-challenged mice.